Mavacamten, a First-in-Class Cardiac Myosin Inhibitor for Obstructive Hypertrophic Cardiomyopathy
Sign Up to like & getrecommendations! Published in 2022 at "Annals of Pharmacotherapy"
DOI: 10.1177/10600280221117812
Abstract: Objective: To assess mavacamten’s role in hypertrophic cardiomyopathy treatment. Data Sources: In addition to clinical guidelines, package inserts, and general reviews, we searched PubMed using the term mavacamten from inception to June 11, 2022. Study… read more here.
Keywords: mavacamten first; hypertrophic cardiomyopathy; first class; obstructive hypertrophic ... See more keywords